Biognosys Enters Collaboration with Leading Life Science Company to Advance Next-generation Proteomics
Biognosys, an innovator and leader in next-generation proteomics technology and solutions for life sciences research, announced today that they have entered a collaboration with Evotec, a life science company that discovers, develops, and provides highly effective therapeutics for patients, to advance the adoption of next-generation proteomics in drug discovery and clinical research.
Evotec has been a long-term user of Biognosys’ software and kits within its research. The two companies are now working closely together to integrate Biognosys’ next-generation proteomics data analysis platform in drug discovery and clinical proteomics.
Under the extended partnership, Evotec will continue to utilize Spectronaut, Biognosys’ flagship data analysis software for data-independent acquisition (DIA) mass spectrometry (MS) based proteomics, in its research. The software employs advanced Search, Artificial Intelligence (AI), and Machine Learning (ML) algorithms to translate data into actionable insights for life science research. Spectronaut enables reproducible and precise quantification of thousands of proteins in a single experiment and provides multidimensional insights into protein expression, function, and structure across all major biological species and sample types.
Additionally, Evotec is implementing Biognosys’ unique workflow for mass spectrometry facility management. This workflow combines Biognosys’ proprietary QuiC software with its patented indexed Retention Time (iRT) technology and iRT Kit to generate near real-time readouts from mass spectrometry instrument raw files for quality control.
The collaboration uniquely combines Evotec’s partnered drug discovery and development business model and focus on data-driven precision medicine, and Biognosys’ expertise and know-how in applying next-generation proteomics to transforming drug discovery and development.
Kristina Beeler, PhD, CBO of Biognosys, comments: “We are excited to deploy the power of proteomics to address some of the key challenges of drug development and work closely with Evotec to de-risk therapeutic assets early on.”
Christoph Schaab, PhD, SVP Head of Proteomics & Metabolomics at Evotec, comments: “Discovery proteomics is increasing its importance to derive functional insights in the early stages of the drug development pipeline. We are thrilled to integrate Biognosys’ proteomics data analysis expertise into Evotec’s pre-clinical and clinical development solutions for the benefit of our biopharma partners.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
About Evotec
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the worldleading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,900 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005750/en/
Contact information
Media Contact Biognosys
Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owlet ® Strengthens Market Leadership as Dream Sight™ Becomes the First Baby Monitor Awarded the SGS Cybersecurity Mark30.10.2025 14:45:00 EET | Press release
Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced that its newest video monitoring device, Dream Sight, is the first and only baby monitor to earn an SGS Cybersecurity Mark, a global certification that recognizes the highest standards in international cybersecurity and privacy. Dream Sight was tested by Brightsight, an SGS company and global leader in cybersecurity evaluations. For parents, this independent recognition provides extra reassurance that Owlet delivers trusted digital solutions backed by strong encryption, secure data management, and advanced privacy safeguards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106669800/en/ Owlet's Dream Sight is the first and only baby monitor to earn an SGS Cybersecurity Mark, a global certification that recognizes the highest standards in international cybersecurity and privacy. “Earning the SGS Cybersecurity Mark un
Crown Bioscience Achieves Second CLIA Certification of 2025 at Suzhou Laboratory30.10.2025 14:30:00 EET | Press release
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced that its Suzhou, China laboratory has received Clinical Laboratory Improvement Amendments (CLIA) certification. This achievement marks the company’s second CLIA certification in 2025, following its San Diego facility earlier this year, underscoring Crown Bioscience’s continued commitment to expanding its global network of compliant, clinical-grade laboratories. Regulated by the Centers for Medicare and Medicaid Services (CMS), CLIA certification sets the highest federal standards for laboratory accuracy, reliability, and quality. The designation affirms that Crown Bioscience’s Suzhou laboratory meets all required compliance benchmarks, providing clients with greater confidence in the biomarker data that supports their clinical development and regulatory submissions. ‘’Earning a second CLIA certification within
2025 Ecolab Watermark ™ Study Reveals Hidden Impact of Artificial Intelligence30.10.2025 14:30:00 EET | Press release
Ecolab, a global sustainability leader offering water solutions and services, today announced findings from its third annual Ecolab Watermark™ Study, which reports on water stewardship around the world. This year’s research highlights water’s connection to timely global trends, including new business opportunities from the rapid growth of artificial intelligence (AI) and consumer concern about its impact on vital natural resources. According to the Watermark Study, a majority of consumers across fifteen countries understand the power demands of AI, but far fewer recognize the hidden impact of AI – the amount of water required to manufacture AI technology and operate data centers. In the United States (U.S.), just 46% of consumers acknowledge the use of water in AI operations compared to 55% recognizing the use of power. In other regions, including Asia Pacific and Latin America, the gap is even more pronounced. “By 2050, the world will have nearly 30% more people and require 47% more e
SLB OneSubsea Secures EPC Contracts from PTTEP for Two Deepwater Projects Offshore Malaysia30.10.2025 14:30:00 EET | Press release
Global energy technology company SLB (NYSE: SLB) announced today the award of two sizeable engineering, procurement, and construction (EPC) contracts by PTT Exploration and Production Public Company Limited (PTTEP) to its OneSubsea™ joint venture. The contracts build on a 20-year collaboration between the two companies and cover the expansion of two fields offshore Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030090404/en/ As part of the EPC contracts, SLB OneSubsea will deliver comprehensive subsea production systems (SPS) for the Alum, Bemban, and Permai deepwater gas fields located in Block H and the Kikeh field, Malaysia’s first deepwater oil project. As part of the EPC contracts, SLB OneSubsea will deliver comprehensive subsea production systems (SPS) for the Alum, Bemban, and Permai deepwater gas fields located in Block H and the Kikeh field, Malaysia’s first deepwater oil project. The scope includes hor
Novotech Maps Global Growth in Radiopharmaceutical Trials30.10.2025 14:05:00 EET | Press release
Novotech, a leading global clinical research organization (CRO) and scientific advisory partner, today released a new white paper detailing the rapid rise of therapeutic radiopharmaceutical research and the operational frameworks needed to support these complex studies at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030722919/en/ The analysis shows that global therapeutic radiopharmaceutical trials have grown from just a handful in 2018 to more than 80 active studies by August 2025, a tenfold increase highlighting the growth in this advancing area of precision oncology. Therapeutic radiopharmaceuticals deliver targeted radiation directly to tumors via beta and alpha emitters, minimizing off-target exposure. The white paper highlights the clinical role of beta emitters such as Lutetium-177, the growing interest in targeted alpha therapy (TAT), and the critical supply-chain challenges posed by short-lived isotopes
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom